UCB SA (OTCMKTS:UCBJY) Short Interest Up 668.9% in August

Posted by Francis Steltz on Sep 11th, 2026

UCB SA (OTCMKTS:UCBJY – Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 14,956 shares, an increase of 668.9% from the August 15th total of 1,945 shares. Based on an average daily volume of 67,990 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Barclays lowered UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research raised UCB from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Finally, Jefferies Financial Group upgraded shares of UCB from a “moderate sell” rating to a “hold” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

Get Our Latest Research Report on UCB

UCB Trading Down 1.4%

Shares of UCBJY opened at $117.06 on Friday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.04 and a current ratio of 1.38. The company has a 50-day moving average price of $131.47 and a two-hundred day moving average price of $141.33. UCB has a 12 month low of $114.53 and a 12 month high of $168.76.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for people living with severe neurological and immunological diseases. The company operates internationally, serving patients and healthcare providers across North America, Europe and other global markets.

Its neurology portfolio includes treatments such as Keppra and Briviact for epilepsy, Vimpat for partial-onset seizures and Fintepla for certain severe seizure disorders. In immunology, UCB markets Cimzia for conditions including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and Crohn’s disease, as well as Bimzelx for several inflammatory skin and joint conditions.

UCB traces its origins to 1928, when it was established in Belgium as Union Chimique Belge.